EDIT
Price
$1.45
Change
-$0.44 (-23.28%)
Updated
Dec 13, 04:59 PM (EDT)
74 days until earnings call
TGTX
Price
$32.05
Change
+$1.36 (+4.43%)
Updated
Dec 13, 04:59 PM (EDT)
81 days until earnings call
Ad is loading...

EDIT vs TGTX

Header iconEDIT vs TGTX Comparison
Open Charts EDIT vs TGTXBanner chart's image
Editas Medicine
Price$1.45
Change-$0.44 (-23.28%)
Volume$74.53K
CapitalizationN/A
TG Therapeutics
Price$32.05
Change+$1.36 (+4.43%)
Volume$54.6K
CapitalizationN/A
EDIT vs TGTX Comparison Chart
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. TGTX commentary
Dec 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and TGTX is a Hold.

COMPARISON
Comparison
Dec 14, 2024
Stock price -- (EDIT: $1.44 vs. TGTX: $32.02)
Brand notoriety: EDIT and TGTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 424% vs. TGTX: 66%
Market capitalization -- EDIT: $156.02M vs. TGTX: $4.98B
EDIT [@Biotechnology] is valued at $156.02M. TGTX’s [@Biotechnology] market capitalization is $4.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $489.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green whileTGTX’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • TGTX’s FA Score: 0 green, 5 red.
According to our system of comparison, TGTX is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 4 TA indicator(s) are bullish while TGTX’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 4 bullish, 4 bearish.
  • TGTX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both EDIT and TGTX are a good buy in the short-term.

Price Growth

EDIT (@Biotechnology) experienced а -32.71% price change this week, while TGTX (@Biotechnology) price change was -5.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.93%. For the same industry, the average monthly price growth was -4.54%, and the average quarterly price growth was +6.84%.

Reported Earning Dates

EDIT is expected to report earnings on Feb 26, 2025.

TGTX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-3.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TGTX($4.98B) has a higher market cap than EDIT($156M). TGTX YTD gains are higher at: 79.684 vs. EDIT (-85.785). TGTX has higher annual earnings (EBITDA): 5.82M vs. EDIT (-222.63M). TGTX has more cash in the bank: 341M vs. EDIT (265M). EDIT has less debt than TGTX: EDIT (38.5M) vs TGTX (254M). TGTX has higher revenues than EDIT: TGTX (265M) vs EDIT (61.8M).
EDITTGTXEDIT / TGTX
Capitalization156M4.98B3%
EBITDA-222.63M5.82M-3,824%
Gain YTD-85.78579.684-108%
P/E RatioN/A39.56-
Revenue61.8M265M23%
Total Cash265M341M78%
Total Debt38.5M254M15%
FUNDAMENTALS RATINGS
EDIT vs TGTX: Fundamental Ratings
EDIT
TGTX
OUTLOOK RATING
1..100
5074
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
85
Overvalued
PROFIT vs RISK RATING
1..100
10059
SMR RATING
1..100
9891
PRICE GROWTH RATING
1..100
9637
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (14) in the Biotechnology industry is significantly better than the same rating for TGTX (85). This means that EDIT’s stock grew significantly faster than TGTX’s over the last 12 months.

TGTX's Profit vs Risk Rating (59) in the Biotechnology industry is somewhat better than the same rating for EDIT (100). This means that TGTX’s stock grew somewhat faster than EDIT’s over the last 12 months.

TGTX's SMR Rating (91) in the Biotechnology industry is in the same range as EDIT (98). This means that TGTX’s stock grew similarly to EDIT’s over the last 12 months.

TGTX's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for EDIT (96). This means that TGTX’s stock grew somewhat faster than EDIT’s over the last 12 months.

TGTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that TGTX’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITTGTX
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 22 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PDIAX21.37N/A
N/A
Virtus KAR Equity Income A
LRSVX24.29N/A
N/A
Lord Abbett Small Cap Value R6
ARUIX12.13N/A
N/A
ARGA Value Institutional
GSPUX41.00N/A
N/A
Goldman Sachs Large Cap Core R6
APDMX36.47N/A
N/A
Artisan Mid Cap Advisor

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with NTLA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-23.81%
NTLA - EDIT
62%
Loosely correlated
-4.87%
CRSP - EDIT
60%
Loosely correlated
-3.57%
BEAM - EDIT
59%
Loosely correlated
-0.46%
VERV - EDIT
54%
Loosely correlated
-8.35%
AURA - EDIT
53%
Loosely correlated
-0.36%
More

TGTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TGTX has been loosely correlated with EDIT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if TGTX jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TGTX
1D Price
Change %
TGTX100%
-3.03%
EDIT - TGTX
45%
Loosely correlated
-5.03%
ALT - TGTX
40%
Loosely correlated
-1.72%
NTLA - TGTX
38%
Loosely correlated
-3.83%
CRNX - TGTX
37%
Loosely correlated
-7.53%
ARRY - TGTX
36%
Loosely correlated
-3.33%
More